NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment …MarketWatch (press release)The results (detailed in Abstract #2528), reported in a poster presented by the NCI, demonstrated that vaccination following rituximab combinat…
Control of disease activity and biologic treatment increase life expectency in …Medical XpressThe study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab…
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical …Healthcare Global (press release)SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patient…
New Treatment Option for Non-Hodgkin Lymphoma Delays Tumour Progression With …MarketWatch (press release)A trial that enrolled 549 patients with certain types of immune system cancers showed that bendamustine and rituximab worked better and was less …
Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN(R) and …MarketWatch (press release)A Phase 2 investigator-sponsored study in patients with stage III/IV CD20+ DLBCL (Abstract # 6633) found that short-duration therapy consisting …
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits …SYS-CON Media (press release)Come to New York and get yourself up to date with the Big Data revolution! As advanced data storage, access and analytics technologies aimed at…
SymBio Announces Results Presented at ASCO 2012 Evaluating …Marketwire (press release)SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM® (Bendamustine) in Combination With Rituximab in Patients …
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits …MarketWatch (press release)TOKYO, Jun 04, 2012 (MARKETWIRE via COMTEX) — SymBio Pharmaceuticals Limited (jasdaq:4582) announced today that results from a multicenter, Phas…
Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI …MarketWatch (press release)Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/ref…
'Rediscovered' lymphoma drug helps double survival: studyMedical XpressThe drug, bendamustine, more than doubled disease progression-free survival when given along with another therapy, rituximab (Rituxan), compared to the drug cocktail that…